Liquidia (NASDAQ:LQDA) Price Target Raised to $92.00

Liquidia (NASDAQ:LQDA) had its price objective boosted by Bank of America from $79.00 to $92.00 in a research note released on Thursday,Benzinga reports. Bank of America currently has a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Wells Fargo & Company boosted their price objective on shares of Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday. Needham & Company LLC upped their price objective on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a report on Thursday, June 4th. Finally, Stephens set a $130.00 target price on Liquidia in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Hold” and a consensus price target of $98.08.

Liquidia Stock Performance

Shares of LQDA stock opened at $74.44 on Thursday. The company has a market capitalization of $6.66 billion, a P/E ratio of 54.34 and a beta of 0.58. Liquidia has a fifty-two week low of $21.15 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.03 and a current ratio of 2.31. The stock has a 50 day moving average price of $78.67 and a two-hundred day moving average price of $55.13.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter in the prior year, the business posted ($0.49) EPS. The firm’s revenue for the quarter was up 1842.1% on a year-over-year basis. Analysts expect that Liquidia will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the completion of the transaction, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This trade represents a 21.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the sale, the director owned 1,176,184 shares in the company, valued at approximately $82,838,639.12. This trade represents a 17.08% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,756,861 shares of company stock valued at $122,981,112. 25.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Farallon Capital Management LLC grew its holdings in Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after purchasing an additional 90,400 shares during the period. Vanguard Group Inc. increased its stake in shares of Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after purchasing an additional 52,671 shares in the last quarter. Opaleye Management Inc. lifted its holdings in shares of Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Finally, Caprock Group LLC raised its position in shares of Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after purchasing an additional 151,832 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).